A new benchmark has been established to assess the ability of artificial intelligence to forecast immune responses. This development has implications for various fields, including drug discovery and cancer immunotherapy, with some outlets suggesting that ai models can improve predictions in these areas. The introduction of this benchmark and related advancements in machine learning and ai are being explored by several research groups and companies.